More CEO watchers put Gilead's Martin on their 'best of 2014' lists

End-of-year bouquets are piling up for Gilead Sciences ($GILD) CEO John Martin. After winning top reviews from the Harvard Business Review for his 2014 performance, Martin has picked up a "best CEO" nod from a prof at Dartmouth's Tuck School of Business. And the investing site Motley Fool puts him among the year's three "most exceptional" corporate chiefs. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.